## PORTLAND EUROPOLL - SPRING 2018

Methodology: ComRes interviewed 230 EU influencers online between $13^{\text {th }}$ March and $25^{\text {th }}$ May 2018 . Data were weighted to be representative of EU influencers by organisation type and MEPs by party and region. ComRes is a member of the British Polling Council and abides by its rules.

All press releases or other publications must be checked with ComRes before use. ComRes requires 48 hours to check a press release unless otherwise agreed.

For information about commissioning research please contact info@comresglobal.com or call +44 (0)20 78718660.

REPUTATION | COMMUNICATIONS | PUBLIC POLICY

Four Millbank | London | SWIP 3JA | T. +44 (0)20 78718660
Rond-Point Schuman / Schumanplein 6|Box 5 | 1040 Bruxelles | T. +32 (0)2 2346382
51/F Raffles City | No. 268 Xi Zang Middle Road | HuangPu District Shanghai | 200001 China | T. +86 (0)21 23127674

## Europoll Spring 2018

Q1_SUM. To what extent, if at all, do you agree or disagree with the following statements? SUMMARY TABL
Base: All respondents
Q1 1. To what extent, if at all, do you agree or disagree with the following statements? Pharmaceutical companies can generally be trusted to behave ethically and responsibly $\qquad$$\cdots 3$Base: All respondents 6
Q1_2. To what extent, if at all, do you agree or disagree with the following statements? EU pharmaceutical companies will be negatively impacted by Brexit
Base: All respondentsQ1_3. To what extent, if at all, do you agree or disagree with the following statements? The pharmaceutical sector should be prioritised by EU negotiators over other industry sectors in Brexit negotiations 9
Base: All respondent
12 Qase: All respondent
Q1_5. To what extent, if at all, do you agree or disagree with the following statements? Trade barriers resulting from the EU-UK Brexit agreement have the potential to inpact supplies of medicines available for patient ..... 15
Base: All respondents
Q1 6. To what extent, if at all, do you agree or disagree with the following statements? Patients' interests need to be given greater priority in the Brexit negotiation process .....  18
Q1_7. To what extent, Iat all, do you agree or disagree with the following statements? Utimate responsibility for patients' access to critical medicines after Brexit lies with EU and UK negotiators rather than pharmaceuical companies ..... 21
Base: All respondents24Q1_8. To what extent, if at all, do you agree or disagree with the following statements? I would like to have greater understanding as to what the pharmaceutical sector needs from a Brexit agreement

## Q1_SUM. To what extent, if at all, do you agree or disagree with the following statements?

## SUMMARY TABLE

Base: All respondents
terests need to be given greater
priority in the Brexit negotiation process
Trade barriers resulting from the EU-UK Brexit agreement have the potential to impac supplies of medicines available for patients

Ultimate responsibility for patients' access to critical medicines after Brexit lies with EU an UK negotiators rather than pharmaceutical companies
EU pharmaceutical companies will be negatively impacted by Brexit
would like to have greater understanding as to what the pharmaceutical sector needs from a Brexit agreement
I would be interested in engaging with pharmaceutical companies directly over pharmaceutical companies directly over
issues of concern to the pharmaceutical industry
Pharmaceutical companies can generally be trusted to behave ethically and responsibly

|  |  |  |  | Somewhat disagree | Strongly disagree | Don't know | No response | NETS |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Strongly agree | Somewhat agree | $\begin{gathered} \text { Neither agree nor } \\ \text { disagree } \end{gathered}$ |  |  |  |  | Agree | Disagree | Mean |
| 230 | 51 | 56 | 59 | 10 | 5 | 33 | 17 | 107 | 15 | 3.77 |
| 100\% | 22\% | 24\% | 25\% | 4\% | 2\% | 14\% | 7\% | 46\% | 6\% |  |
| 230 | 23$10 \%$ | 70 | 36 | 27 | 18 | 39 | 17 | 93 | 45 | 3.31 |
| 100\% |  | 30\% | 16\% | 12\% | 8\% | 17\% | 7\% | $41 \%$ | 20\% |  |
| 230 | $\begin{aligned} & 33 \\ & 14 \% \end{aligned}$ | 49$21 \%$ | 40$17 \%$ | $\begin{aligned} & 30 \\ & 13 \% \end{aligned}$ | $\begin{aligned} & 19 \\ & 8 \% \end{aligned}$ | $\begin{aligned} & 40 \\ & 17 \% \end{aligned}$ | $\begin{aligned} & 19 \\ & 8 \% \end{aligned}$ | $\begin{aligned} & 82 \\ & 36 \% \end{aligned}$ | $\begin{aligned} & 49 \\ & 21 \% \end{aligned}$ | 3.28 |
| 100\% |  |  |  |  |  |  |  |  |  |  |
| 230 | 16$7 \%$ | 57 | 47 | 21 | 27 | 47 | 16 | 72 | 48 | 3.08 |
| 100\% |  | 25\% | 20\% | 9\% | 12\% | 20\% | 7\% | 32\% | 21\% |  |
| 230 | 11 | 55 | 56 | 22 | 29 | 37 | 20 | 65 | 51 | 2.98 |
| 100\% | 5\% | 24\% | 25\% | 10\% | 13\% | 16\% | 9\% | 28\% | 22\% |  |
| 230 | 10$4 \%$ | 31$14 \%$ | 44$19 \%$ | 32$14 \%$ | $\begin{aligned} & 52 \\ & 23 \% \end{aligned}$ | $\begin{aligned} & 40 \\ & 17 \% \end{aligned}$ | $\begin{aligned} & 20 \\ & 9 \% \end{aligned}$ | $\begin{aligned} & 42 \\ & 18 \% \end{aligned}$ | $\begin{aligned} & 85 \\ & 37 \% \end{aligned}$ | 2.50 |
| 100\% |  |  |  |  |  |  |  |  |  |  |
| 230 | 4$2 \%$ | 28$12 \%$ | $\begin{aligned} & 51 \\ & 22 \% \end{aligned}$ | 64 28\% | $\begin{aligned} & 36 \\ & 15 \% \end{aligned}$ | $\begin{aligned} & 29 \\ & 13 \% \end{aligned}$ | $\begin{gathered} 18 \\ 8 \% \end{gathered}$ | $\begin{aligned} & 32 \\ & 14 \% \end{aligned}$ | 100 | 2.46 |
| 100\% |  |  |  |  |  |  |  |  | 43\% |  |

## Europoll Spring 2018

Q1_SUM. To what extent, if at all, do you agree or disagree with the following statements?

## SUMMARY TABLE

Base: All respondents

The pharmaceutical sector should be prioritised by EU negotiators over other industry sectors in Brexit negotiations

|  |  |  |  |  |  |  | Don't know | No response | NETS |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Strongly agree |  | Somewhat agree | Neither agree nor disagree | Somewhat disagree | Strongly disagree |  |  | Agree |  | Disagree |  | Mean |
| 230 |  | 3 | 25 | 54 | 47 | 45 | 35 | 20 | 28 |  | 92 |  | 2.40 |
| 100\% |  | 2\% | 11\% | 24\% | 21\% | 20\% | 15\% | 9\% |  | 12\% |  | 40\% |  |

## Q1_1. To what extent, if at all, do you agree or disagree with the following statements?

Pharmaceutical companies can generally be trusted to behave ethically and responsibly Base: All respondents

## Unweighted Total

Weighted Total

Strongly agree
(5)

Somewhat agree
Neither agree nor disagree

Somewhat disagree
Strongly disagree

|  |  | Brussels Influencers |  |  | PARTY |  |  |  |  |  | AGE |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | MEPs | All influencers | EU Institution Staff | Brussels Opinion Formers | EPP | S\&D | ALDE | ECR | EFDD/ENF | Other | $\begin{aligned} & 18-24 \\ & \text { years } \\ & \hline \end{aligned}$ | $\begin{aligned} & 25-34 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 35-44 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 45-54 \\ & \text { years } \\ & \hline \end{aligned}$ | $\begin{aligned} & 55-64 \\ & \text { years } \\ & \hline \end{aligned}$ | 65 years or over |
| 230 | 76 | 154 | 43 | 111 | 20 | 15 | 10 | 11 | 5 | 15 | 1 | 22 | 67 | 64 | 52 | 22 |
| 230 | 76 | 154 | 77 | 77 | 22 | 19 | 7 | 7 | 4 | 17 | 1 | 20 | 66 | 64 | 49 | 29 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 4 | * | 4 | 2 | 2 | - | - | - | * | - | - | - | - | 2 | - | 3 | - |
| 2\% | 1\% | 3\% | 2\% | 3\% | - | - | - | 7\% | - | - | - | - | 3\% | - | 5\% | - |
| 28 | 17 | 11 | 2 | 9 | 6 | 7 | * | 3 | - | 1 | - | 2 | 6 | 10 | 7 | 4 |
| 12\% | 23\% | 7\% | 2\% | 12\% | 26\% | 35\% | 6\% | 42\% | - | 9\% | - | 11\% | 9\% | 15\% | 14\% | 13\% |
| 51 | 22 | 29 | 13 | 17 | 11 | $5$ | $1$ | $3$ | $1$ | $2$ | - | $2$ | 15 | 19 |  | 5 |
| $22 \%$ | 28\% | 19\% | 16\% | 22\% | 48\% | $25 \%$ | 13\% | 37\% | 17\% | 13\% | - | 11\% | 23\% | 29\% | 20\% | 19\% |
| 64 | 15 | 49 | 30 | 19 | 2 | 7 | 4 | - | - | 2 | - | 5 | 15 | 13 | 19 | 13 |
| 28\% | 19\% | 32\% | 40\% | 24\% | 8\% | 35\% | 57\% | - | - | 14\% | - | 23\% | 22\% | 20\% | 39\% | 44\% |
| 36 | 13 | 22 | 9 | 13 | 1 | - | * | 1 | 3 | 9 | 1 | 5 | 13 | 8 | 4 | 4 |
| 15\% | 18\% | 14\% | 12\% | 17\% | 4\% | - | 6\% | 8\% | 67\% | 53\% | 100\% | 27\% | 20\% | 13\% | 9\% | 14\% |
| 29 | 2 | 28 | 14 | 13 | - | - | - | - | 1 | 1 | - | 2 | 10 | 10 | 4 | 2 |
| 13\% | 2\% | 18\% | 19\% | 17\% | - | - | - | - | 17\% | 7\% |  | 13\% | 16\% | 15\% | 9\% | 6\% |
|  | $7$ |  |  |  |  |  |  | * |  |  | - | 3 | 5 |  |  |  |
| $8 \%$ | 9\% | 7\% | 9\% | 5\% | 14\% | 6\% | 18\% | 7\% | - | 4\% | - | 16\% | 8\% | 8\% | 6\% | 4\% |
| 32 | 18 | 15 | 4 | 11 | 6 | 7 | * | 3 | - | 1 | - | 2 | 8 | 10 | 9 | 4 |
| 14\% | 23\% | 10\% | 5\% | 14\% | 26\% | 35\% | 6\% | 48\% | - | 9\% | - | 11\% | 12\% | 15\% | 19\% | 13\% |
| 100 | 28 | 71 | 39 | 32 | 3 | 7 | 4 | 1 | 3 | 11 | 1 | 10 | 27 | 21 | 23 | 17 |
| 43\% | 37\% | 46\% | 51\% | 41\% | 13\% | 35\% | 63\% | 8\% | 67\% | 67\% | 100\% | 50\% | 42\% | 33\% | 47\% | 58\% |
| 2.46 | 2.65 | 2.35 | 2.23 | 2.47 | 3.11 | 3.00 | 2.23 | 3.41 | 1.40 | 1.74 | 1.00 | 2.07 | 2.39 | 2.59 | 2.63 | 2.34 |

## Q1_1. To what extent, if at all, do you agree or disagree with the following statements?

Pharmaceutical companies can generally be trusted to behave ethically and responsibly Base: All respondents

## Unweighted Total

Weighted Total
Strongly agree

Somewhat agree
Neither agree nor disagree

Somewhat disagree
Strongly disagree

Don't know
No response
NETS
Net: Agree
Net: Disagree

Mean score

|  | GENDER |  | REGION |  |  |  |  | LENGTH OF SERVICE |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Male | Female | Western | Nordic/ Northern | Mediterranean | Eastern | $\begin{gathered} \text { Other } \\ \text { unspecified } \end{gathered}$ | Less than a year | $1-5$ years | 6-10 years | More than 10 years |
| 230 | 144 | 82 | 68 | 62 | 43 | 47 | 10 | 6 | 69 | 52 | 102 |
| 230 | 146 | 79 | 73 | 55 | 38 | 55 | 9 | 7 | 64 | 55 | 103 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 4 | 3 | 1 | 2 | * | - | 2 | - | - | - | - | 4 |
| 2\% | 2\% | 2\% | 3\% | 1\% | - | 3\% | - | - | - | - | 4\% |
| 28 | 17 | 11 | 11 | 5 | 7 | 2 | 2 | 2 | 14 | 5 | 7 |
| 12\% | 12\% | 14\% | 15\% | 10\% | 20\% | 4\% | 20\% | 26\% | 23\% | 9\% | 7\% |
| 51 | 36 | 15 | 17 | 12 | 5 | 14 | 3 | 1 | 10 | 15 | 24 |
| 22\% | 25\% | 19\% | 23\% | 23\% | 13\% | 25\% | 30\% | 18\% | 15\% | 28\% | 24\% |
| 64 | 45 | 19 | 10 | 23 | 12 | 16 | 2 | - | 14 | 13 | 37 |
| 28\% | 31\% | 24\% | 14\% | 42\% | 32\% | 29\% | 27\% | - | 22\% | 23\% | 36\% |
| 36 | 17 | 18 | 17 | 8 | 2 | 9 | - | 4 | 15 | 9 | 7 |
| 15\% | 12\% | 23\% | 23\% | 14\% | 7\% | 16\% | - | 56\% | 23\% | 16\% | 7\% |
| 29 | 18 | 9 | 10 | 6 | 8 | 5 | 1 | - | 6 | 6 | 18 |
| 13\% | 12\% | 12\% | 13\% | 11\% | 22\% | 9\% | 8\% | - | 9\% | 11\% | 17\% |
| 18 | 10 | 6 | 7 | * | 3 | 7 | 1 | - | 5 | 7 | 6 |
| 8\% | 7\% | 7\% | 9\% | 1\% | 7\% | 13\% | 15\% | - | 8\% | 13\% | 5\% |
| 32 | 20 | 12 | 13 | 6 | 7 | 4 | 2 | 2 | 14 | 5 | 11 |
| 14\% | 14\% | 16\% | 18\% | 11\% | 20\% | 8\% | 20\% | 26\% | 23\% | 9\% | 11\% |
| 100 | 62 | 37 | 27 | 30 | 15 | 25 | 2 | 4 | 29 | 21 | 44 |
| 43\% | 43\% | 47\% | 37\% | 55\% | 39\% | 46\% | 27\% | 56\% | 46\% | 39\% | 43\% |
| 2.46 | 2.52 | 2.36 | 2.50 | 2.35 | 2.65 | 2.35 | 2.90 | 2.13 | 2.44 | 2.40 | 2.55 |

## Q1_1. To what extent, if at all, do you agree or disagree with the following statements?

Pharmaceutical companies can generally be trusted to behave ethically and responsibly Base: All respondents

Unweighted Total
Weighted Total

Strongly agree
Somewhat agree

Neither agree nor disagree
Somewhat disagree

Strongly disagree

Don't know

No response

NETS
Net: Agree

Net: Disagree

Mean score


EU pharmaceutical companies will be negatively impacted by Brexit
Base: All respondents

## Unweighted Total

Weighted Total
Strongly agree

> (5)

Somewhat agree
Neither agree nor disagree
(3)

Somewhat disagree
Strongly disagree

|  |  |  | Brussels Influencers |  |  | PARTY |  |  |  |  |  | AGE |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Total | MEPs | $\begin{gathered} \text { All } \\ \text { influencers } \end{gathered}$ | EU Institution Staff | Brussels <br> Opinion <br> Formers | EPP | S\&D | ALDE | ECR | EFDD/ENF | Other | $\begin{aligned} & 18-24 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 25-34 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 35-44 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 45-54 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 55-64 \\ & \text { years } \end{aligned}$ | 65 years or over |
|  | 230 | 76 | 154 | 43 | 111 | 20 | 15 | 10 | 11 | 5 | 15 | 1 | 22 | 67 | 64 | 52 | 22 |
|  | 230 | 76 | 154 | 77 | 77 | 22 | 19 | 7 | 7 | , | 17 | 1 | 20 | 66 | 64 | 49 | 29 |
|  | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| (5) | 16 | 6 | 10 | 2 | 8 | 2 | 1 | * | 2 | - | - | - | 2 | 5 | 4 | 5 | - |
|  | 7\% | 7\% | 7\% | 2\% | 11\% | 8\% | 5\% | 6\% | 33\% | - | - | - | 11\% | 8\% | 6\% | 10\% | - |
| (4) | 57 | 17 | 39 | 18 | 22 | 8 | 4 | 1 | 1 | 2 | 1 | - | 2 | 16 | 17 | 17 | 5 |
|  | 25\% | 23\% | 26\% | 23\% | 28\% | 34\% | 22\% | 19\% | 15\% | 48\% | 7\% | - | 11\% | 24\% | 26\% | 35\% | 16\% |
| (3) | 47 | 23 | 24 | 13 | 11 | 8 | 8 | 1 | 2 | 1 | 2 | 1 | 1 | 12 | 13 | 10 | 9 |
|  | 20\% | 30\% | 15\% | 16\% | 14\% | 37\% | 43\% | 18\% | 24\% | 35\% | 14\% | 100\% | 7\% | 19\% | 20\% | 20\% | 31\% |
| (2) | 21 | 9 | 12 | 7 | 5 | 2 | 2 | 2 | 1 | - | 3 | - | - | 6 | 6 | 4 | 5 |
|  | 9\% | 12\% | 8\% | 9\% | 6\% | 7\% | 12\% | 24\% | 15\% | - | 16\% | - | - | 10\% | 10\% | 7\% | 17\% |
| (1) | 27 | 12 | 15 | 13 | 3 | 2 | 1 | - | - | 1 | 8 | - | 2 | 8 | 6 | 5 | 6 |
|  | 12\% | 16\% | 10\% | 16\% | 4\% | 10\% | 6\% | - | - | 17\% | 48\% | - | 11\% | 12\% | 10\% | 9\% | 21\% |
|  | 47 | 4 | 42 | 18 | 24 | - | 1 | 1 | * | - | 2 | - | 9 | 12 | 13 | 9 | 3 |
|  | 20\% | 6\% | 27\% | 23\% | 32\% | - | 6\% | 14\% | 7\% | - | 11\% | - | 45\% | 18\% | 21\% | 18\% | 10\% |
|  | 16 | $4$ | 11 | $7$ | $4$ |  | $1$ | $1$ |  |  |  | - | $3$ | $6$ |  | - |  |
|  | $7 \%$ | 6\% | 7\% | 9\% | 5\% | 4\% | 6\% | $18 \%$ | 7\% | - | 4\% | - | 16\% | 9\% | 8\% | - | 4\% |
|  | 72 | 23 | 50 | 20 | 30 | 10 | 5 | 2 | 3 | 2 | 1 | - | 4 | 21 | 21 | 22 | 5 |
|  | 32\% | 30\% | 32\% | 26\% | 39\% | 43\% | 27\% | 25\% | 48\% | 48\% | 7\% | - | 21\% | 32\% | 32\% | 45\% | 16\% |
|  | 48 | 21 | 27 | 20 | 8 | 4 | 3 | 2 | 1 | 1 | 11 | - | 2 | 15 | 13 | 8 | 11 |
|  | 21\% | 28\% | 18\% | 26\% | 10\% | 16\% | 18\% | 24\% | 15\% | 17\% | 64\% | - | 11\% | 22\% | 19\% | 17\% | 38\% |
|  | 3.08 | 2.93 | 3.17 | 2.79 | 3.57 | 3.26 | 3.09 | 3.09 | 3.77 | 3.15 | 1.76 | 3.00 | 3.26 | 3.07 | 3.13 | 3.35 | 2.50 |

## Q1_2. To what extent, if at all, do you agree or disagree with the following statements?

## EU pharmaceutical companies will be negatively impacted by Brexit

Base: All respondents

## Unweighted Total <br> Weighted Total

Strongly agree

Somewhat agree
Neither agree nor disagree

Somewhat disagree
Strongly disagree

Don't know
No response
NETS
Net: Agree
Net: Disagree

Mean score


Q1_2. To what extent, if at all, do you agree or disagree with the following statements?
EU pharmaceutical companies will be negatively impacted by Brexit
Base: All respondents

Unweighted Total
Weighted Total

Strongly agree
Somewhat agree

Neither agree nor disagree
Somewhat disagree

Strongly disagree

Don't know

No response
NETS
Net: Agree

Net: Disagree

Mean score

|  | POLICY AREA |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Transport | Energy | Financial services | Health/ pharmaceuticals | Technology/ industry/ manufacturing | Biotechnology/ chemicals | Food and drink/ agriculture | Environment/ climate change | IT/ telecommunications | The internal market | $\begin{gathered} \hline \text { Innovation/ } \\ \text { science/ } \\ \text { research } \\ \text { and } \\ \text { development } \end{gathered}$ | None of these |
| 230 | 50 | 53 | 38 | 37 | 36 | 17 | 63 | 83 | 23 | 47 | 64 | 55 |
| 230 | 49 | 48 | 40 | 31 | 34 | 13 | 61 | 80 | 22 | 43 | 61 | 57 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 16 | 4 | 2 | 3 | 3 | 5 | 1 | 3 | 6 | 5 | 6 | 6 | 2 |
| 7\% | 8\% | 3\% | 9\% | 9\% | 14\% | 5\% | 6\% | 7\% | 22\% | 14\% | 10\% | 4\% |
| 57 | 17 | 17 | 12 | 11 | 12 | 4 | 18 | 23 | 8 | 11 | 14 | 13 |
| 25\% | 35\% | 37\% | 30\% | 37\% | 35\% | 32\% | 30\% | 29\% | 37\% | 26\% | 23\% | 22\% |
| 47 | 6 | 6 | 9 | 5 | 3 | 2 | 11 | 12 | 1 | 4 | 8 | 15 |
| 20\% | 13\% | 13\% | 21\% | 16\% | 10\% | 18\% | 18\% | 15\% | 3\% | 9\% | 14\% | 26\% |
| 21 | 3 | 4 | 3 | 4 | 3 | 2 | 5 | 3 | 4 | 2 | 6 | 11 |
| 9\% | 5\% | 8\% | 7\% | 12\% | 9\% | 15\% | 7\% | 4\% | 18\% | 5\% | 9\% | 19\% |
| 27 | 5 | 4 | 2 | 3 | 2 | 1 | 15 | 14 | - | 9 | 12 | 2 |
| 12\% | 10\% | 9\% | 5\% | 11\% | 5\% | 5\% | 24\% | 18\% | - | 20\% | 20\% | 4\% |
| 47 | 13 | 13 | $9$ | 4 | $8$ | $3$ | $8$ | 21 | $4$ | 10 | 12 | 6 |
| 20\% | 25\% | $28 \%$ | 22\% | 13\% | 25\% | $24 \%$ | 13\% | 26\% | 20\% | 22\% | 20\% | 10\% |
| 16 | 2 | 1 | 2 | 1 | - | - | 1 | 1 | - | 2 | 2 | 9 |
| 7\% | 4\% | 2\% | 6\% | 2\% | - | - | 1\% | 1\% | - | 4\% | 4\% | 15\% |
| 72 | 21 | 19 | 16 | 14 | 17 | 5 | 22 | 29 | 13 | 18 | 20 | 15 |
| 32\% | 43\% | 40\% | 39\% | 46\% | 50\% | 37\% | 36\% | 36\% | 59\% | 41\% | 33\% | 26\% |
| 48 | 8 | 8 | 5 | 7 | 5 | 3 | 19 | 18 | 4 | 11 | 18 | 13 |
| 21\% | 15\% | 17\% | 12\% | 23\% | 15\% | 20\% | 31\% | 22\% | 18\% | 24\% | 29\% | 23\% |
| 3.08 | 3.34 | 3.25 | 3.41 | 3.26 | 3.59 | 3.22 | 2.83 | 3.04 | 3.79 | 3.14 | 2.93 | 3.02 |

## Europoll Spring 2018

Q1_3. To what extent, if at all, do you agree or disagree with the following statements?
The pharmaceutical sector should be prioritised by EU negotiators over other industry sectors in Brexit negotiations Base: All respondents

## Unweighted Total

Weighted Total
Strongly agree
(5)

Somewhat agree
Neither agree nor disagree

Somewhat disagree
(2)

Strongly disagree

|  |  | Brussels Influencers |  |  | PARTY |  |  |  |  |  | AGE |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | MEPs | All influencers | EU Institution Staff | Brussels <br> Opinion <br> Formers | EPP | S\&D | ALDE | ECR | EFDD/ENF | Other | $\begin{aligned} & 18-24 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 25-34 \\ & \text { years } \\ & \hline \end{aligned}$ | $\begin{aligned} & 35-44 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 45-54 \\ & \text { years } \\ & \hline \end{aligned}$ | $\begin{aligned} & 55-64 \\ & \text { years } \\ & \hline \end{aligned}$ | 65 years or over |
| 230 | 76 | 154 | 43 | 111 | 20 | 15 | 10 | 11 | 5 | 15 | 1 | 22 | 67 | 64 | 52 | 22 |
| 230 | 76 | 154 | 77 | 77 | 22 | 19 | 7 | 7 | 4 | 17 | 1 | 20 | 66 | 64 | 49 | 29 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 3 | - | 3 | - | 3 | - | - | - | - | - | - | - | - | - | 1 | 2 | 1 |
| 2\% | - | 2\% | - | 5\% | - | - | - | - | - | - | - | - | - | 1\% | 4\% | 2\% |
| 25 | 12 | 13 | 7 | 6 | 5 | 3 | - | 1 | 1 | 2 | 1 | - | 10 | 8 | 4 |  |
| 11\% | 16\% | 8\% | 9\% | 7\% | 22\% | 17\% | - | 17\% | 17\% | 11\% | 100\% | - | 16\% | 12\% | 7\% | 8\% |
| 54 | 17 | 37 | 18 | 19 | 5 | 5 | 1 | 4 | - | 1 | - | 3 | 15 | 17 | 16 | 4 |
| 24\% | 22\% | 24\% | 23\% | 25\% | 23\% | 29\% | 19\% | 55\% | - | 7\% | - | 14\% | 23\% | 26\% | 32\% | 13\% |
| 47 | 20 | 27 | 13 | 15 | 5 | 4 | 1 | * | 3 | 6 | - | 3 | 12 | 12 | 8 | 13 |
| 21\% | 27\% | 18\% | 16\% | 19\% | 24\% | 21\% | 18\% | 7\% | 67\% | 38\% | - | 14\% | 19\% | 18\% | 16\% | 43\% |
| 45 | 17 | 28 | 16 | 12 | 3 | 5 | 2 | 1 | 1 | 5 | - | 8 | 10 | 12 | 10 | 5 |
| 20\% | 22\% | 18\% | 21\% | 15\% | 12\% | 27\% | 30\% | 15\% | 17\% | 33\% | - | 40\% | 15\% | 18\% | 21\% | 18\% |
| 35 | 3 | 32 | 16 | 16 | 1 | - | 1 | - | - | 1 | - | 2 | 12 | 11 | 7 | 3 |
| 15\% | 4\% | 21\% | 21\% | 21\% | 4\% | - | 14\% | - | - | 7\% | - | 13\% | 18\% | 16\% | 13\% | 10\% |
| 20 | $7$ | 13 | $7$ | $6$ | $3$ | $1$ | $1$ |  |  |  | - | $4$ | 6 |  |  | 1 |
| 9\% | 9\% | 9\% | 9\% | 8\% | 14\% | 6\% | 18\% | 7\% | - | 4\% | - | 20\% | 9\% | 9\% | 6\% | 4\% |
| 28 | 12 | 16 | 7 | 9 | 5 | 3 | - | 1 | 1 | 2 | 1 | - | 10 | 8 | 6 | 3 |
| 12\% | 16\% | 11\% | 9\% | 12\% | 22\% | 17\% | - | 17\% | 17\% | 11\% | 100\% | - | 16\% | 13\% | 12\% | 10\% |
| 92 | 37 | 55 | 29 | 26 | 8 | 9 | 3 | 2 | 3 | 12 | - | 11 | 22 | 23 | 18 | 18 |
| 40\% | 49\% | 36\% | 37\% | 34\% | 37\% | 48\% | 48\% | 22\% | 83\% | 71\% |  | 54\% | 34\% | 36\% | 37\% | 62\% |
| 2.40 | 2.36 | 2.42 | 2.30 | 2.53 | 2.67 | 2.39 | 1.83 | 2.79 | 2.17 | 1.97 | 4.00 | 1.62 | 2.54 | 2.47 | 2.48 | 2.22 |

Q1_3. To what extent, if at all, do you agree or disagree with the following statements?
The pharmaceutical sector should be prioritised by EU negotiators over other industry sectors in Brexit negotiations Base: All respondents

Unweighted Total
Weighted Total
Strongly agree

Somewhat agree
Neither agree nor disagree

Somewhat disagree
Strongly disagree
Don't know
No response
NETS
Net: Agree
Net: Disagree

Mean score

|  | GENDER |  | REGION |  |  |  |  | LENGTH OF SERVICE |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Male | Female | Western | Nordic/ Northern | Mediterranean | Eastern | $\begin{gathered} \text { Other } \\ \text { unspecified } \end{gathered}$ | Less than a year | $1-5$ years | 6-10 years | More than 10 years |
| 230 | 144 | 82 | 68 | 62 | 43 | 47 | 10 | 6 | 69 | 52 | 102 |
| 230 | 146 | 79 | 73 | 55 | 38 | 55 | 9 | 7 | 64 | 55 | 103 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 3 | 1 | 3 | 2 | - | 1 | 1 | - | - | - | 1 | 3 |
| 2\% | * | 4\% | 3\% | - | 2\% | 1\% | - | - | - | 1\% | 3\% |
| 25 | 16 | 9 | 3 | 6 | 5 | 11 | - | - | 8 | 6 | 10 |
| 11\% | 11\% | 11\% | 4\% | 10\% | 13\% | 20\% | - | - | 13\% | 10\% | 10\% |
| 54 | 34 | 20 | 16 | 10 | 11 | 13 | 5 | 1 | 18 | 13 | 23 |
| 24\% | 23\% | 26\% | 22\% | 19\% | 28\% | 23\% | 50\% | 15\% | 28\% | 23\% | 22\% |
| 47 | 38 | 9 | 20 | 14 | 6 | 6 | 1 | 2 | 13 | 13 | 19 |
| 21\% | 26\% | 11\% | 28\% | 26\% | 16\% | 11\% | 8\% | 36\% | 21\% | 24\% | 18\% |
| 45 | 25 | 20 | 12 | 14 | 9 | 8 | 2 | 3 | 12 | 7 | 24 |
| 20\% | 17\% | 25\% | 16\% | 25\% | 24\% | 15\% | 20\% | 38\% | 19\% | 12\% | 23\% |
| 35 | 21 | 11 | 12 | 10 | 3 | 9 | 1 | 1 | 7 | 9 | 19 |
| 15\% | 15\% | 14\% | 16\% | 19\% | 8\% | 17\% | 8\% | 11\% | 10\% | 16\% | 18\% |
| 20 | 10 | 7 | 8 | * | 3 | 7 | 1 | - | 6 | 7 | 7 |
| 9\% | 7\% | 9\% | 11\% | 1\% | 8\% | 13\% | 15\% | - | 9\% | 13\% | 7\% |
| 28 | 16 | 12 | 5 | 6 | 6 | 12 | - | - | 8 | 7 | 13 |
| 12\% | 11\% | 15\% | 7\% | 10\% | 15\% | 21\% | - | - | 13\% | 12\% | 12\% |
| 92 | 64 | 29 | 32 | 28 | 15 | 14 | 2 | 5 | 25 | 20 | 42 |
| 40\% | 44\% | 36\% | 44\% | 51\% | 40\% | 26\% | 27\% | 74\% | 40\% | 36\% | 41\% |
| 2.40 | 2.37 | 2.44 | 2.31 | 2.18 | 2.43 | 2.73 | 2.39 | 1.74 | 2.43 | 2.50 | 2.35 |

## Q1_3. To what extent, if at all, do you agree or disagree with the following statements?

The pharmaceutical sector should be prioritised by EU negotiators over other industry sectors in Brexit negotiations Base: All respondents

Unweighted Total
Weighted Total

Strongly agree
Somewhat agree

Neither agree nor disagree
Somewhat disagree

Strongly disagree

Don't know

No response

NETS
Net: Agree

Net: Disagree
Mean score

|  | POLICY AREA |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Transport | Energy | Financial services | Health/ pharmaceuticals | Technology/ industry/ manufacturing | Biotechnology/ chemicals | Food and drink/ agriculture | Environment/ climate change | IT/ <br> telecommunications | The internal market | Innovation/ science/ research and development | None of these |
| 230 | 50 | 53 | 38 | 37 | 36 | 17 | 63 | 83 | 23 | 47 | 64 | 55 |
| 230 | 49 | 48 | 40 | 31 | 34 | 13 | 61 | 80 | 22 | 43 | 61 | 57 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 3 | - | 1 | 1 | 3 | - | 1 | 2 | 1 | 1 | 1 | 2 | 1 |
| 2\% | - | 1\% | 2\% | 9\% | - | 11\% | 3\% | 2\% | 3\% | 2\% | 3\% | 1\% |
| 25 | 2 | 4 | 7 | 4 | 6 | - | 5 | 7 | 3 | 6 | 7 | 5 |
| 11\% | 5\% | 9\% | 17\% | 14\% | 18\% | - | 9\% | 8\% | 16\% | 14\% | 12\% | 9\% |
| 54 | 12 | 13 | 9 | 6 | 12 | 4 | 12 | 16 | 6 | 8 | 16 | 13 |
| 24\% | 25\% | 28\% | 23\% | 21\% | 35\% | 28\% | 20\% | 21\% | 29\% | 18\% | 27\% | 23\% |
| 47 | 10 | 8 | 9 | 10 | 6 | 3 | 18 | 19 | 5 | 9 | 9 | 13 |
| 21\% | 21\% | 17\% | 24\% | 33\% | 18\% | 21\% | 30\% | 24\% | 21\% | 21\% | 15\% | 22\% |
| 45 | 11 | 14 | 6 | 2 | 5 | 2 | 14 | 21 | 2 | 11 | 12 | 10 |
| 20\% | 23\% | 28\% | 14\% | 7\% | 14\% | 16\% | 24\% | 26\% | 11\% | 25\% | 19\% | 18\% |
| 35 | 11 | 6 | 6 | 4 | 5 | 3 | 6 | 12 | 4 | 7 | 10 | 6 |
| 15\% | 23\% | 13\% | 14\% | 12\% | 16\% | 24\% | 9\% | 15\% | 20\% | 16\% | 17\% | 10\% |
| 20 | 2 | 2 | 2 | 1 | - | - | 3 | 4 | - | 2 | 5 | 9 |
| 9\% | 4\% | 4\% | 6\% | 5\% | - | - | 6\% | 4\% | - | 5\% | 8\% | 16\% |
| 28 | 2 | 5 | 8 | 7 | 6 | 1 | 7 | 8 | 4 | 7 | 9 | 6 |
| 12\% | 5\% | 10\% | 19\% | 23\% | 18\% | 11\% | 12\% | 10\% | 19\% | 15\% | 15\% | 10\% |
| 92 | 22 | 22 | 15 | 12 | 11 | 5 | 33 | 39 | 7 | 20 | 20 | 23 |
| 40\% | 44\% | 45\% | 38\% | 40\% | $31 \%$ | 37\% | 53\% | 49\% | 32\% | 46\% | 34\% | 40\% |
| 2.40 | 2.16 | 2.25 | 2.61 | 2.83 | 2.68 | 2.58 | 2.28 | 2.21 | 2.74 | 2.31 | 2.54 | 2.35 |

## Europoll Spring 2018

Q1_4. To what extent, if at all, do you agree or disagree with the following statements?
I would be interested in engaging with pharmaceutical companies directly over issues of concern to the pharmaceutical industry Base: All respondents

## Unweighted Total

Weighted Total

Strongly agree

> (5)

Somewhat agree
Neither agree nor disagree
(3)

Somewhat disagree
Strongly disagree

|  |  |  | Brussels Influencers |  |  | PARTY |  |  |  |  |  | AGE |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Total | MEPs | All influencers | EU Institution Staff | Brussels <br> Opinion <br> Formers | EPP | S\&D | ALDE | ECR | EFDD/ENF | Other | $\begin{aligned} & 18-24 \\ & \text { years } \\ & \hline \end{aligned}$ | $\begin{aligned} & 25-34 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 35-44 \\ & \text { years } \\ & \hline \end{aligned}$ | $\begin{aligned} & 45-54 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 55-64 \\ & \text { years } \end{aligned}$ | 65 years or over |
|  | 230 | 76 | 154 | 43 | 111 | 20 | 15 | 10 | 11 | 5 | 15 | 1 | 22 | 67 | 64 | 52 | 22 |
|  | 230 | 76 | 154 | 77 | 77 | 22 | 19 | 7 | 7 | 4 | 17 | 1 | 20 | 66 | 64 | 49 | 29 |
|  | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| (5) | 10 $4 \%$ | 3 $5 \%$ | 7 $4 \%$ | 2 $2 \%$ | 5 $6 \%$ | - | 2 $11 \%$ | - | - | - | 1 $9 \%$ | 1 $100 \%$ | $\stackrel{1}{4 \%}$ | ${ }^{4}$ | 1 $1 \%$ | 2 $5 \%$ | 1 $5 \%$ |
| (4) | 31 | 16 | 15 | 7 | ${ }^{8}$ | ${ }^{6}$ | 3 $17 \%$ | 1 $18 \%$ | $\stackrel{2}{2}$ | ${ }_{1}^{1}$ | 2 $13 \%$ | - | 1 | 7 $11 \%$ | 13 | $\stackrel{5}{11 \%}$ | ${ }^{4}$ |
|  | 14\% | 21\% | 10\% | 9\% | 11\% | 29\% | 17\% | 18\% | 28\% | 19\% | 13\% | - | 7\% | 11\% | 21\% | 11\% | 15\% |
| (3) | 44 | 22 | 22 | 9 | 13 | 9 | 7 | * | 2 | 1 | 18 | - | 11 | 13 | 11 | 11 | 7 |
|  | 19\% | 29\% | 14\% | 12\% | 17\% | 40\% | 39\% | 6\% | 32\% | 30\% | 11\% | - | 11\% | 21\% | 17\% | 22\% | 24\% |
| (2) | 32 | 19 | 13 | ${ }_{7}^{5}$ | 8 10 | ${ }^{6}$ | $\stackrel{2}{2}$ | 1 | ${ }^{2}$ | 1 | 6 | - | 1 | 8 | 10 | 9 | 4 |
|  | 14\% | 25\% | 8\% | 7\% | 10\% | 27\% | 12\% | 13\% | 33\% | 35\% | 37\% | - | 7\% | 13\% | 15\% | 19\% | 13\% |
| (1) | 52 | 6 | 47 | 29 | 18 | - | 2 | 2 | - | - | 2 | - | 10 | 15 | 10 | 12 | 6 |
|  | 23\% | 8\% | 30\% | 37\% | 23\% | - | 9\% | 30\% | - | - | 11\% | - | 49\% | 23\% | 15\% | 24\% | 22\% |
|  | 40 | 5 | 35 | 16 | 19 | - | 1 | 1 | - | 1 | 2 | - | 1 | 12 | 13 | 9 | 3 |
|  | 17\% | 7\% | 23\% | 21\% | 24\% | - | 6\% | 14\% | - | 17\% | 14\% | - | 7\% | 18\% | 21\% | 19\% | 12\% |
|  | 20 | 4 | 15 | 9 | 6 | 1 | 1 | 1 | * | - | 1 | - | 3 | 6 | 6 | 1 | 3 |
|  | 9\% | 6\% | 10\% | 12\% | 8\% | 4\% | 6\% | 18\% | 7\% | - | 4\% | - | 16\% | 9\% | 10\% | 1\% | 11\% |
|  | 42 | 19 | 22 | 9 | 13 | 6 | 5 | 1 | 2 | 1 | 4 | 1 | 2 | 11 | 14 | 8 | 6 |
|  | 18\% | 26\% | 14\% | 12\% | 17\% | 29\% | 28\% | 18\% | 28\% | 19\% | 22\% | 100\% | 11\% | 17\% | 22\% | 16\% | 19\% |
|  | 85 | 25 | 60 | 34 | 26 | 6 | 4 | 3 | 2 | 1 | 8 | - | 11 | 23 | 20 | 21 | 10 |
|  | 37\% | 33\% | 39\% | 44\% | 33\% | 27\% | 21\% | 43\% | 33\% | 35\% | 49\% | - | 56\% | 35\% | 31\% | 43\% | 34\% |
|  | 2.50 | 2.88 | 2.25 | 2.00 | 2.51 | 3.01 | 3.09 | 2.19 | 2.95 | 2.80 | 2.64 | 5.00 | 1.83 | 2.53 | 2.67 | 2.42 | 2.59 |

## Europoll Spring 2018

Q1_4. To what extent, if at all, do you agree or disagree with the following statements?
I would be interested in engaging with pharmaceutical companies directly over issues of concern to the pharmaceutical industry Base: All respondents

Unweighted Total
Weighted Total
Strongly agree

Somewhat agree
Neither agree nor disagree

Somewhat disagree
Strongly disagree

Don't know
No response
NETS
Net: Agree
Net: Disagree

Mean score

|  | GENDER |  | REGION |  |  |  |  | LENGTH OF SERVICE |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Male | Female | Western | Nordic/ Northern | Mediterranean | Eastern | $\begin{gathered} \text { Other } \\ \text { unspecified } \end{gathered}$ | Less than a year | $1-5$ years | 6-10 years | More than 10 years |
| 230 | 144 | 82 | 68 | 62 | 43 | 47 | 10 | 6 | 69 | 52 | 102 |
| 230 | 146 | 79 | 73 | 55 | 38 | 55 | 9 | 7 | 64 | 55 | 103 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 10 | 6 | 4 | 1 | 6 | 1 | 2 | - | - | 4 | 1 | 6 |
| 4\% | 4\% | 5\% | 2\% | 10\% | 4\% | 3\% | - | - | 6\% | 1\% | 5\% |
| 31 | 22 | 9 | 11 | 11 | 3 | 5 | 2 | - | 8 | 8 | 15 |
| 14\% | 15\% | 12\% | 15\% | 19\% | 9\% | 9\% | 20\% | - | 12\% | 15\% | 15\% |
| 44 | 33 | 11 | 14 | 6 | 9 | 12 | 3 | 1 | 13 | 16 | 13 |
| 19\% | 23\% | 13\% | 19\% | 12\% | 24\% | 22\% | 30\% | 15\% | 21\% | 28\% | 13\% |
| 32 | 22 | 10 | 12 | 9 | 5 | 5 | 1 | 4 | 13 | 8 | 8 |
| 14\% | 15\% | 13\% | 17\% | 16\% | 14\% | 9\% | 8\% | 56\% | 21\% | 14\% | 8\% |
| 52 | 29 | 23 | 14 | 15 | 7 | 15 | 2 | 2 | 16 | 9 | 26 |
| 23\% | 20\% | 29\% | 20\% | 26\% | 18\% | 27\% | 20\% | 28\% | 25\% | 16\% | 25\% |
| 40 | 23 | 15 | 14 | 7 | 9 | 10 | 1 | - | 5 | 9 | 26 |
| 17\% | 16\% | 19\% | 19\% | 12\% | 23\% | 18\% | 8\% | - | 7\% | 17\% | 25\% |
| 20 | 10 | 7 | 7 | 2 | 3 | 6 | 1 | - | 6 | 5 | 9 |
| 9\% | 7\% | 9\% | 9\% | 4\% | 8\% | 11\% | 15\% | - | 9\% | 9\% | 9\% |
| 42 | 28 | 13 | 12 | 16 | 5 | 7 | 2 | - | 12 | 9 | 21 |
| 18\% | 19\% | 17\% | 17\% | 29\% | 13\% | 12\% | 20\% | - | 18\% | 16\% | 20\% |
| 85 | 51 | 34 | 27 | 24 | 12 | 20 | 2 | 6 | 29 | 17 | 34 |
| 37\% | 35\% | 42\% | 36\% | 43\% | 32\% | 37\% | 27\% | 85\% | 45\% | 30\% | 33\% |
| 2.50 | 2.59 | 2.32 | 2.48 | 2.65 | 2.52 | 2.30 | 2.65 | 1.87 | 2.46 | 2.61 | 2.51 |

## Q1_4. To what extent, if at all, do you agree or disagree with the following statements?

I would be interested in engaging with pharmaceutical companies directly over issues of concern to the pharmaceutical industry Base: All respondents

Unweighted Total
Weighted Total


Strongly agree
Somewhat agree

Neither agree nor disagree
Somewhat disagree

Strongly disagree

Don't know

No response

NETS
Net: Agree

Net: Disagree
Mean score


## Europoll Spring 2018

Q1_5. To what extent, if at all, do you agree or disagree with the following statements?
Trade barriers resulting from the EU-UK Brexit agreement have the potential to impact supplies of medicines available for patients Base: All respondents

## Unweighted Total

Weighted Total
Strongly agree


Somewhat agree
Neither agree nor disagree

Somewhat disagree
Strongly disagree
(1)

Don't know
No response

NETS
Net: Agree
Net: Disagree

Mean score

|  |  | Brussels Influencers |  |  | PARTY |  |  |  |  |  | AGE |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | MEPs | All influencers | EU Institution Staff | Brussels <br> Opinion <br> Formers | EPP | S\&D | ALDE | ECR | EFDD/ENF | Other | $\begin{aligned} & 18-24 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 25-34 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 35-44 \\ & \text { years } \\ & \hline \end{aligned}$ | $\begin{aligned} & 45-54 \\ & \text { years } \\ & \hline \end{aligned}$ | $\begin{aligned} & 55-64 \\ & \text { years } \\ & \hline \end{aligned}$ | 65 years or over |
| 230 | 76 | 154 | 43 | 111 | 20 | 15 | 10 | 11 | 5 | 15 | 1 | 22 | 67 | 64 | 52 | 22 |
| 230 | 76 | 154 | 77 | 77 | 22 | 19 | 7 | 7 | 4 | 17 | 1 | 20 | 66 | 64 | 49 | 29 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 23 | 7 | 17 | 4 | 13 | 2 | 3 | * | 1 | 1 | - | - | 1 | 8 | 4 | 9 | 1 |
| 10\% | 9\% | 11\% | 5\% | 17\% | 7\% | 16\% | 6\% | 13\% | 19\% | - | - | 4\% | 12\% | 6\% | 18\% | 5\% |
| 70 | 20 | 50 | 30 | 19 | 7 | 4 | 1 | 4 | 2 | 1 | 1 | 6 | 18 | 24 | 17 | 5 |
| 30\% | 27\% | 32\% | 40\% | 25\% | 32\% | 23\% | 20\% | 59\% | 48\% | 7\% | 100\% | 28\% | 27\% | 37\% | 34\% | 19\% |
| 36 | 16 | 20 | 7 | 12 | 5 | 4 | 1 | 1 | 1 | 4 | - | 1 | 10 | 6 | 6 | 12 |
| 16\% | 21\% | 13\% | 9\% | 16\% | 22\% | 21\% | 18\% | 15\% | 17\% | 26\% | - | 7\% | 16\% | 9\% | 13\% | 41\% |
| 27 | 18 | 10 | 5 | 4 | 5 | 4 | 2 | * | - | 6 | - | 1 | 9 | 7 | 4 | 5 |
| 12\% | 23\% | 6\% | 7\% | 5\% | 21\% | 21\% | 31\% | 7\% | - | 39\% | - | 4\% | 14\% | 11\% | 9\% | 19\% |
| 18 | 8 | 9 | 7 | 2 | 3 | 1 | * | - | 1 | 3 | - | 1 | 5 | 6 | 3 | 3 |
| 8\% | 11\% | 6\% | 9\% | 3\% | 15\% | 6\% | 6\% | - | 17\% | 18\% | - | 4\% | 8\% | 9\% | 6\% | 10\% |
| 39 | 2 | 36 | 16 | 20 | - | 1 | - | - | - | 1 | - | 7 | 9 | 12 | 10 | - |
| 17\% | 3\% | 24\% | 21\% | 26\% | - | 6\% | - | - | - | 7\% | - | 38\% | 13\% | 18\% | 20\% | - |
| 17 | 4 | 13 | 7 | 6 | 1 | 1 | 1 | * | - | 1 | - | 3 | 6 | 6 | - | 2 |
| 7\% | 6\% | 8\% | 9\% | 7\% | 4\% | 6\% | 18\% | 7\% | - | 4\% | - | 16\% | 9\% | 9\% | - | 7\% |
| 93 | 27 | 67 | 34 | 33 | 9 | 8 | 2 | 5 | 3 | 1 | 1 | 6 | 26 | 28 | 26 | 7 |
| 41\% | 35\% | 43\% | 44\% | 42\% | 38\% | 39\% | 26\% | 72\% | 67\% | 7\% | 100\% | 32\% | 40\% | 43\% | 52\% | 23\% |
| 45 | 26 | 19 | 13 | 6 | 8 | 5 | 3 | * | 1 | 9 | - | 1 | 15 | 13 | 8 | 8 |
| 20\% | 34\% | 12\% | 16\% | 8\% | 35\% | 27\% | 37\% | 7\% | 17\% | 56\% | - | 7\% | 22\% | 20\% | 15\% | 29\% |
| 3.31 | 2.98 | 3.53 | 3.33 | 3.73 | 2.95 | 3.25 | 2.86 | 3.84 | 3.52 | 2.25 | 4.00 | 3.53 | 3.28 | 3.28 | 3.61 | 2.88 |

## Europoll Spring 2018

Q1_5. To what extent, if at all, do you agree or disagree with the following statements?
Trade barriers resulting from the EU-UK Brexit agreement have the potential to impact supplies of medicines available for patients Base: All respondents

## Unweighted Total

Weighted Total
Strongly agree

Somewhat agree
Neither agree nor disagree

Somewhat disagree
Strongly disagree

Don't know
No response
NETS
Net: Agree
Net: Disagree

Mean score


Q1_5. To what extent, if at all, do you agree or disagree with the following statements?
Trade barriers resulting from the EU-UK Brexit agreement have the potential to impact supplies of medicines available for patients Base: All respondents

Unweighted Total
Weighted Total

Strongly agree
Somewhat agree

Neither agree nor disagree
Somewhat disagree

Strongly disagree

Don't know
No response
NETS
Net: Agree

Net: Disagree

Mean score


Q1_6. To what extent, if at all, do you agree or disagree with the following statements?
Patients' interests need to be given greater priority in the Brexit negotiation process Base: All respondents

## Unweighted Total

Weighted Total
Strongly agree
(5)
(5)

Somewhat agree
Neither agree nor disagree
(3)

Somewhat disagree
Strongly disagree


## Q1_6. To what extent, if at all, do you agree or disagree with the following statements?

## Patients' interests need to be given greater priority in the Brexit negotiation process

 Base: All respondents
## Unweighted Total

Weighted Total
Strongly agree

Somewhat agree
Neither agree nor disagree

Somewhat disagree
Strongly disagree

Don't know
No response
NETS
Net: Agree
Net: Disagree

Mean score

|  | GENDER |  | REGION |  |  |  |  | LENGTH OF SERVICE |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Male | Female | Western | Nordic/ Northern | Mediterranean | Eastern | Other unspecified | Less than a year | $1-5$ years | 6-10 years | More than 10 years |
| 230 | 144 | 82 | 68 | 62 | 43 | 47 | 10 | 6 | 69 | 52 | 102 |
| 230 | 146 | 79 | 73 | 55 | 38 | 55 | 9 | 7 | 64 | 55 | 103 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 51 | 31 | 20 | 12 | 12 | 10 | 15 | 2 | 1 | 11 | 10 | 29 |
| 22\% | 21\% | 25\% | 16\% | 21\% | 27\% | 27\% | 27\% | 15\% | 17\% | 17\% | 28\% |
| 56 | 36 | 19 | 16 | 11 | 14 | 14 | 1 | - | 24 | 14 | 17 |
| 24\% | 25\% | 25\% | 22\% | 21\% | 38\% | 25\% | 8\% | - | 38\% | 26\% | 17\% |
| 59 | 39 | 19 | 25 | 17 | 4 | 9 | 4 | 4 | 15 | 16 | 23 |
| 25\% | 27\% | 24\% | 35\% | 30\% | 11\% | 16\% | 42\% | 56\% | 24\% | 29\% | 23\% |
| 10 | 7 | 4 | 1 | 3 | 3 | 3 | - | 1 | 4 | 2 | 3 |
| 4\% | 4\% | 5\% | 1\% | 6\% | 8\% | 5\% | - | 18\% | 6\% | 3\% | 3\% |
| 5 | 5 | - | 1 | 1 | 1 | 2 | - | - | 1 | 2 | 2 |
| 2\% | 3\% | - | 1\% | 3\% | 2\% | 3\% | - | - | 1\% | 3\% | 2\% |
| 33 | 18 | 12 | 14 | 10 | 2 | 6 | 1 | 1 | 5 | 5 | 22 |
| 14\% | 13\% | 15\% | 19\% | 19\% | 7\% | 11\% | 8\% | 11\% | 7\% | 10\% | 21\% |
| 17 | 10 | 5 | 5 | * | 3 | 7 | 1 | - | 4 | 6 | 6 |
| 7\% | 7\% | 6\% | 7\% | 1\% | 7\% | 14\% | 15\% | - | 7\% | 12\% | 6\% |
| 107 | 68 | 39 | 28 | 23 | 25 | 28 | 3 | 1 | 35 | 24 | 46 |
| 46\% | 46\% | 50\% | 38\% | 42\% | 66\% | 51\% | 35\% | 15\% | 55\% | 43\% | 45\% |
| 15 | 11 | 4 | 1 | 5 | 4 | 5 | - | 1 | 5 | 4 | 5 |
| 6\% | 8\% | 5\% | 2\% | 9\% | 10\% | 9\% | - | 18\% | 7\% | 6\% | 5\% |
| 3.77 | 3.70 | 3.89 | 3.69 | 3.64 | 3.93 | 3.88 | 3.80 | 3.15 | 3.73 | 3.65 | 3.91 |

Q1_6. To what extent, if at all, do you agree or disagree with the following statements?
Patients' interests need to be given greater priority in the Brexit negotiation process Base: All respondents

Unweighted Total
Weighted Total

Strongly agree
Somewhat agree

Neither agree nor disagree
Somewhat disagree

Strongly disagree
Don't know
No response
NETS
Net: Agree

Net: Disagree

Mean score

|  | POLICY AREA |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Transport | Energy | Financial services | Health/ pharmaceuticals | $\begin{gathered} \text { Technology/ } \\ \text { industry/ } \\ \text { manufacturing } \\ \hline \end{gathered}$ | $\begin{gathered} \text { Biotechnology/ } \\ \text { chemicals } \end{gathered}$ | Food and drink/ agriculture | Environment/ climate change | IT/ telecommunications | The internal market |  | None of these |
| 230 | 50 | 53 | 38 | 37 | 36 | 17 | 63 | 83 | 23 | 47 | 64 | 55 |
| 230 | 49 | 48 | 40 | 31 | 34 | 13 | 61 | 80 | 22 | 43 | 61 | 57 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 51 | 6 | 12 | 4 | 11 | 6 | 2 | 13 | 20 | 4 | 8 | 13 | 15 |
| 22\% | 13\% | 24\% | 11\% | 37\% | 17\% | 16\% | 22\% | 25\% | 16\% | 19\% | 22\% | 26\% |
| 56 | 16 | 18 | 12 | 5 | 11 | 4 | 16 | 22 | 10 | 11 | 16 | 11 |
| 24\% | 33\% | 37\% | 29\% | 17\% | 32\% | 33\% | 25\% | 27\% | 46\% | 26\% | 27\% | 19\% |
| 59 | 13 | 6 | 13 | 7 | 9 | 3 | 24 | 19 | 2 | 12 | 15 | 11 |
| 25\% | 26\% | 12\% | 31\% | 23\% | 27\% | 21\% | 40\% | 24\% | 11\% | 28\% | 24\% | 20\% |
| 10 | 1 | 3 | 1 | 1 | 1 | - | 1 | 3 | 1 | 1 |  | 6 |
| 4\% | 3\% | 7\% | 4\% | 2\% | 2\% | - | 1\% | 4\% | 3\% | 2\% | 1\% | 11\% |
| 5 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | - |
| 2\% | 3\% | 1\% | 5\% | 2\% | 4\% | 5\% | 2\% | 3\% | 3\% | 2\% | 4\% | - |
| 33 | 9 | 6 | 6 | 6 | 6 | 3 | 5 | 13 | 4 | 9 | 12 | 5 |
| 14\% | 19\% | 14\% | 14\% | 18\% | 18\% | 24\% | 9\% | 17\% | 20\% | 21\% | 19\% | 9\% |
| 17 | 2 | 2 | 2 | - | - | - | 1 | 1 | - | 2 | 2 | 9 |
| 7\% | 4\% | 5\% | 6\% | - | - | - | 1\% | 1\% | - | 4\% | 3\% | 16\% |
| 107 | 23 | 29 | 16 | 17 | 16 | 6 | 29 | 41 | 13 | 19 | 29 | 25 |
| 46\% | 46\% | 61\% | 40\% | 54\% | 49\% | 49\% | 47\% | 52\% | 62\% | 45\% | 49\% | 44\% |
| 15 | 3 | 4 | 4 | 1 | 2 | 1 | 2 | 5 | 1 | 1 | 3 | 6 |
| 6\% | 6\% | 8\% | 9\% | 5\% | 6\% | 5\% | 3\% | 7\% | 6\% | 3\% | 5\% | 11\% |
| 3.77 | 3.65 | 3.93 | 3.46 | 4.03 | 3.67 | 3.72 | 3.70 | 3.81 | 3.86 | 3.78 | 3.78 | 3.79 |

## Europoll Spring 2018

Q1_7. To what extent, if at all, do you agree or disagree with the following statements?
Ultimate responsibility for patients' access to critical medicines after Brexit lies with EU and UK negotiators rather than pharmaceutical companies Base: All respondents

## Unweighted Total

Weighted Total

Strongly agree
(5)

Somewhat agree
Neither agree nor disagree
(4)

Somewhat disagree
Strongly disagree

|  |  |  | Brussels Influencers |  |  | PARTY |  |  |  |  |  | AGE |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Total | MEPs | $\begin{gathered} \text { All } \\ \text { influencers } \end{gathered}$ | EU Institution Staff | Brussels <br> Opinion <br> Formers | EPP | S\&D | ALDE | ECR | EFDD/ENF | Other | $\begin{aligned} & 18-24 \\ & \text { years } \\ & \hline \end{aligned}$ | $\begin{aligned} & 25-34 \\ & \text { years } \\ & \hline \end{aligned}$ | $\begin{aligned} & 35-44 \\ & \text { years } \end{aligned}$ | $\begin{aligned} & 45-54 \\ & \text { years } \\ & \hline \end{aligned}$ | $\begin{aligned} & 55-64 \\ & \text { years } \\ & \hline \end{aligned}$ | 65 years or over |
|  | 230 | 76 | 154 | 43 | 111 | 20 | 15 | 10 | 11 | 5 | 15 | 1 | 22 | 67 | 64 | 52 | 22 |
|  | 230 | 76 | 154 | 77 | 77 | 22 | 19 | 7 | 7 | 4 | 17 | 1 | 20 | 66 | 64 | 49 | 29 |
|  | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| (5) | 33 | 10 | 23 | 7 | 16 | 1 | 3 | 1 | 3 | 1 | - | 1 | 2 | 7 | 13 | 9 | 1 |
|  | 14\% | 13\% | 15\% | 9\% | 21\% | 3\% | 16\% | 18\% | 48\% | 35\% | - | 100\% | 11\% | 10\% | 20\% | 18\% | 4\% |
| (4) | 49 | 16 | 33 | 20 | 13 | 7 | 2 | 2 | 1 | 2 | 2 | - | 4 | 12 | 16 | 8 | 9 |
|  | 21\% | 21\% | 21\% | 26\% | 17\% | 31\% | 12\% | 31\% | 15\% | 48\% | 11\% | - | 20\% | 19\% | 25\% | 16\% | 30\% |
| (3) | 40 | 23 | 17 | 7 | 10 | 9 | 9 | 1 | 2 | - | 3 | - | 2 | 9 | 7 | 15 | 7 |
|  | 17\% | 31\% | 11\% | 9\% | 13\% | 41\% | 48\% | 13\% | 22\% | - | 16\% | - | 11\% | 14\% | 11\% | 30\% | 24\% |
| (2) | 30 | 7 | 23 | 14 | 8 | 3 | 1 | * | 1 | - | 3 | - | 3 | 9 | 8 | 5 | 4 |
|  | 13\% | 10\% | 15\% | 19\% | 11\% | 12\% | 6\% | 6\% | 8\% | - | 15\% | - | 16\% | 14\% | 13\% | 10\% | 15\% |
| (1) | 19 | 9 | 10 | 5 | 4 | 1 | 1 | * | - | 1 | 6 | - | 1 | 8 | 4 | 4 | 2 |
|  | 8\% | 12\% | 6\% | 7\% | 5\% | 5\% | 6\% | 6\% | - | 17\% | 36\% | - | 4\% | 12\% | 6\% | 9\% | 9\% |
|  | 40 | 6 | 34 | 14 | 20 | 1 | 1 | * | - | - | 3 | - | 5 | 13 | 10 | 7 | 4 |
|  | 17\% | 7\% | 22\% | 19\% | 26\% | 4\% | 6\% | 7\% | - |  | 18\% | - | 23\% | 20\% | 16\% | 15\% | 14\% |
|  | 19 | $4$ | 15 | $9$ | $6$ | $1$ | 1 | $1$ |  | - |  | - | 3 | 8 | 6 |  |  |
|  | 8\% | 6\% | 9\% | 12\% | 7\% | 4\% | 6\% | 18\% | 7\% | - | 4\% | - | 16\% | 11\% | 9\% | 1\% | 4\% |
|  | 82 | 26 | 56 | 27 | 29 | 7 | 5 | 3 | 5 | 3 | 2 | 1 | 6 | 19 | 29 | 17 | 10 |
|  | 36\% | 34\% | 36\% | 35\% | 38\% | 33\% | 28\% | 50\% | 63\% | 83\% | 11\% | 100\% | 30\% | 29\% | 46\% | 35\% | 34\% |
|  | 49 | 17 | 32 | 20 | 12 | 4 | 2 | 1 | 1 | 1 | 8 | - | 4 | 17 | 12 | 9 | 7 |
|  | 21\% | 22\% | 21\% | 26\% | 16\% | 17\% | 12\% | 12\% | 8\% | 17\% | 51\% | - | 20\% | 26\% | 18\% | 19\% | 23\% |
|  | 3.28 | 3.15 | 3.36 | 3.17 | 3.55 | 3.14 | 3.29 | 3.68 | 4.10 | 3.85 | 2.04 | 5.00 | 3.29 | 3.03 | 3.56 | 3.30 | 3.08 |

## Europoll Spring 2018

## Q1_7. To what extent, if at all, do you agree or disagree with the following statements?

Ultimate responsibility for patients' access to critical medicines after Brexit lies with EU and UK negotiators rather than pharmaceutical companies Base: All respondents

## Unweighted Total

Weighted Total
Strongly agree

Somewhat agree
Neither agree nor disagree

Somewhat disagree
Strongly disagree

Don't know
No response
NETS
Net: Agree
Net: Disagree

Mean score

|  | GENDER |  | REGION |  |  |  |  | LENGTH OF SERVICE |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Male | Female | Western | Nordic/ Northern | Mediterranean | Eastern | Other unspecified | Less than a year | 1-5 years | 6-10 years | More than 10 years |
| 230 | 144 | 82 | 68 | 62 | 43 | 47 | 10 | 6 | 69 | 52 | 102 |
| 230 | 146 | 79 | 73 | 55 | 38 | 55 | 9 | 7 | 64 | 55 | 103 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 33 | 17 | 16 | 11 | 11 | 8 | 3 | - | 2 | 9 | 3 | 18 |
| 14\% | 12\% | 20\% | 15\% | 21\% | 20\% | 5\% | - | 26\% | 14\% | 6\% | 18\% |
| 49 | 35 | 14 | 10 | 19 | 6 | 13 | 1 | 1 | 10 | 12 | 27 |
| 21\% | 24\% | 18\% | 14\% | 34\% | 16\% | 24\% | 8\% | 11\% | 16\% | 21\% | 26\% |
| 40 | 31 | 9 | 14 | 10 | 6 | 7 | 3 | * | 13 | 13 | 14 |
| 17\% | 21\% | 12\% | 19\% | 18\% | 17\% | 12\% | 35\% | 7\% | 20\% | 23\% | 14\% |
| 30 | 20 | 10 | 13 | 1 | 5 | 8 | 3 | - | 11 | 11 | 8 |
| 13\% | 14\% | 13\% | 18\% | 3\% | 12\% | 14\% | 35\% | - | 17\% | 19\% | 8\% |
| 19 | 11 | 7 | 5 | 4 | 4 | 6 | - | 4 | 7 | 3 | 5 |
| 8\% | 8\% | 9\% | 7\% | 7\% | 11\% | 11\% | - | 56\% | 10\% | 6\% | 5\% |
| 40 | 23 | 14 | 13 | 10 | 6 | 11 | 1 | - | 8 | 9 | 23 |
| 17\% | 16\% | 18\% | 18\% | 18\% | 15\% | 19\% | 8\% | - | 13\% | 16\% | 22\% |
| 19 | 8 | 8 | 6 | * | 3 | 8 | 1 | - | 7 | 5 | 7 |
| 8\% | 6\% | 10\% | 8\% | 1\% | 8\% | 15\% | 15\% | - | 10\% | 9\% | 7\% |
| 82 | 52 | 30 | 22 | 30 | 14 | 16 | 1 | 2 | 19 | 15 | 45 |
| 36\% | 36\% | 38\% | 30\% | 54\% | 37\% | 29\% | 8\% | 37\% | 29\% | 27\% | 44\% |
| 49 | 32 | 17 | 18 | 5 | 9 | 14 | 3 | 4 | 18 | 14 | 14 |
| 21\% | 22\% | 22\% | 25\% | 9\% | 23\% | 25\% | 35\% | 56\% | 28\% | 25\% | 13\% |
| 3.28 | 3.23 | 3.36 | 3.18 | 3.73 | 3.30 | 2.96 | 2.65 | 2.50 | 3.07 | 3.03 | 3.60 |

## Q1_7. To what extent, if at all, do you agree or disagree with the following statements?

Ultimate responsibility for patients' access to critical medicines after Brexit lies with EU and UK negotiators rather than pharmaceutical companies Base: All respondents

Unweighted Total
Weighted Total

Strongly agree
Somewhat agree

Neither agree nor disagree
Somewhat disagree

Strongly disagree

Don't know

No response

NETS
Net: Agree

Net: Disagree
Mean score

|  | POLICY AREA |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Transport | Energy | Financial services | Health/ pharmaceuticals | Technology/ industry/ manufacturing | Biotechnology/ chemicals | Food and drink/ agriculture | Environment/ climate change | IT/ <br> telecommunications | The internal market | $\begin{aligned} & \hline \text { Innovation/ } \\ & \text { science/ } \\ & \text { research } \\ & \text { and } \\ & \text { development } \\ & \hline \end{aligned}$ | None of these |
| 230 | 50 | 53 | 38 | 37 | 36 | 17 | 63 | 83 | 23 | 47 | 64 | 55 |
| 230 | 49 | 48 | 40 | 31 | 34 | 13 | 61 | 80 | 22 | 43 | 61 | 57 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 33 | 3 | 4 | 4 | 4 | 2 | 1 | 10 | 11 | 5 | 6 | 8 | 10 |
| 14\% | 6\% | 9\% | 10\% | 15\% | 6\% | 11\% | 16\% | 13\% | 25\% | 14\% | 13\% | 17\% |
| 49 | 11 | 12 | 12 | 9 | 9 | 4 | 10 | 15 | 5 | 8 | 17 | 10 |
| 21\% | 23\% | 26\% | 30\% | 29\% | 27\% | 28\% | 17\% | 19\% | 25\% | 18\% | 27\% | 18\% |
| 40 | 11 | 7 | 7 | 4 | 7 | 1 | 15 | 15 | 2 | 5 | 9 | 8 |
| 17\% | 21\% | 15\% | 19\% | 14\% | 20\% | 11\% | 24\% | 18\% | 8\% | 11\% | 15\% | 13\% |
| 30 | 5 | 11 | 4 | 5 | 6 | 3 | 10 | 16 | 4 | 6 | 7 | 8 |
| 13\% | 9\% | 22\% | 10\% | 18\% | 19\% | 20\% | 16\% | 20\% | 18\% | 13\% | 12\% | 15\% |
| 19 | 9 | 4 | 4 | 2 | 3 | 1 | 9 | 8 | - | 6 | 5 | 2 |
| 8\% | 18\% | 9\% | 10\% | 6\% | 9\% | 5\% | 15\% | 10\% | - | 15\% | 8\% | 4\% |
| 40 | 10 | 8 | 6 | 5 | 6 | 3 | 7 | 14 | 5 | 11 | 12 | 8 |
| 17\% | 19\% | 16\% | 16\% | 16\% | 18\% | 24\% | 12\% | 18\% | 23\% | 25\% | 20\% | 14\% |
| 19 | 2 |  | 2 | 1 | - | - | $1$ | 1 | - | $2$ |  | 11 |
| 8\% | 4\% | 4\% | 6\% | 2\% | - | - | 1\% | 1\% | - | 4\% | 4\% | 19\% |
| 82 | 14 | 16 | 16 | 13 | 11 | 5 | 20 | 26 | 11 | 14 | 25 | 20 |
| 36\% | 28\% | 34\% | 40\% | 44\% | 33\% | 39\% | 33\% | 33\% | 51\% | 33\% | 41\% | 35\% |
| 49 | 13 | 15 | 8 | 7 | 10 | 3 | 18 | 24 | 4 | 12 | 12 | 11 |
| 21\% | 27\% | 31\% | 20\% | 24\% | 28\% | 26\% | 30\% | 30\% | 18\% | 28\% | 20\% | 19\% |
| 3.28 | 2.85 | 3.03 | 3.26 | 3.35 | 3.02 | 3.25 | 3.06 | 3.07 | 3.76 | 3.06 | 3.34 | 3.44 |

## Europoll Spring 2018

Q1_8. To what extent, if at all, do you agree or disagree with the following statements?
I would like to have greater understanding as to what the pharmaceutical sector needs from a Brexit agreement Base: All respondents

## Unweighted Total

Weighted Total
Strongly agree
(5)

Somewhat agree
Neither agree nor disagree

Somewhat disagree
Strongly disagree


## Q1_8. To what extent, if at all, do you agree or disagree with the following statements?

I would like to have greater understanding as to what the pharmaceutical sector needs from a Brexit agreement Base: All respondents

## Unweighted Total

Weighted Total
Strongly agree

Somewhat agree
Neither agree nor disagree

Somewhat disagree
Strongly disagree

Don't know
No response
NETS
Net: Agree
Net: Disagree

Mean score

|  | GENDER |  | REGION |  |  |  |  | LENGTH OF SERVICE |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Male | Female | Western | Nordic/ Northern | Mediterranean | Eastern | $\begin{gathered} \text { Other } \\ \text { unspecified } \end{gathered}$ | Less than a year | $1-5$ years | 6-10 years | More than 10 years |
| 230 | 144 | 82 | 68 | 62 | 43 | 47 | 10 | 6 | 69 | 52 | 102 |
| 230 | 146 | 79 | 73 | 55 | 38 | 55 | 9 | 7 | 64 | 55 | 103 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 11 | 6 | 5 | 3 | 4 | 3 | 1 | - | - | 4 | 3 | 3 |
| 5\% | 4\% | 6\% | 4\% | 7\% | 8\% | 2\% | - | - | 7\% | 5\% | 3\% |
| 55 | 39 | 16 | 16 | 14 | 8 | 15 | 1 | 2 | 19 | 11 | 22 |
| 24\% | 27\% | 20\% | 22\% | 26\% | 22\% | 27\% | 8\% | 33\% | 29\% | 19\% | 22\% |
| 56 | 39 | 16 | 17 | 12 | 11 | 14 | 3 | - | 13 | 13 | 31 |
| 25\% | 27\% | 20\% | 23\% | 22\% | 29\% | 25\% | 30\% | - | 21\% | 23\% | 30\% |
| 22 | 11 | 11 | 11 | 6 | 1 | 5 | - | 4 | 10 | 4 | 5 |
| 10\% | 8\% | 14\% | 15\% | 10\% | 3\% | 9\% | - | 56\% | 15\% | 7\% | 5\% |
| 29 | 17 | 12 | 9 | 5 | 6 | 7 | 2 | 1 | 7 | 6 | 15 |
| 13\% | 12\% | 15\% | 12\% | 10\% | 16\% | 12\% | 20\% | 11\% | 10\% | 11\% | 15\% |
| 37 | 21 | 15 | 10 | 12 | 5 | 7 | 2 | - | 7 | 11 | 18 |
| 16\% | 14\% | 19\% | 14\% | 21\% | 13\% | 13\% | 27\% | - | 11\% | 20\% | 18\% |
| 20 | 13 | 5 | 7 | 2 | 3 | 6 | 1 | - | 4 | 8 | 8 |
| 9\% | 9\% | 6\% | 10\% | 4\% | 8\% | 11\% | 15\% | - | 7\% | 15\% | 8\% |
| 65 | 45 | 21 | 19 | 18 | 12 | 16 | 1 | 2 | 23 | 14 | 26 |
| 28\% | 31\% | 26\% | 26\% | 32\% | 31\% | 29\% | 8\% | 33\% | 36\% | 25\% | 25\% |
| 51 | 28 | 23 | 20 | 11 | 7 | 12 | 2 | 4 | 16 | 10 | 20 |
| 22\% | 19\% | 29\% | 27\% | 20\% | 19\% | 21\% | 20\% | 67\% | 25\% | 18\% | 20\% |
| 2.98 | 3.04 | 2.85 | 2.88 | 3.13 | 3.05 | 2.98 | 2.45 | 2.56 | 3.08 | 3.00 | 2.92 |

Q1_8. To what extent, if at all, do you agree or disagree with the following statements?
I would like to have greater understanding as to what the pharmaceutical sector needs from a Brexit agreement Base: All respondents

Unweighted Total
Weighted Total

Strongly agree
Somewhat agree

Neither agree nor disagree
Somewhat disagree

Strongly disagree
Don't know

No response
NETS
Net: Agree

Net: Disagree

Mean score

|  | POLICY AREA |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total | Transport | Energy | Financial services | Health/ pharmaceuticals | $\begin{gathered} \text { Technology/ } \\ \text { industry/ } \\ \text { manufacturing } \\ \hline \end{gathered}$ | $\begin{aligned} & \text { Biotechnology/ } \\ & \text { chemicals } \end{aligned}$ | Food and drink/ agriculture | Environment/ climate change | IT/ <br> telecommunications | The internal market | Innovation/ science/ research and development | None of these |
| 230 | 50 | 53 | 38 | 37 | 36 | 17 | 63 | 83 | 23 | 47 | 64 | 55 |
| 230 | 49 | 48 | 40 | 31 | 34 | 13 | 61 | 80 | 22 | 43 | 61 | 57 |
| 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% | 100\% |
| 11 | 2 | 1 | 1 | 1 | 1 | - | 1 | 2 | \% | 3 | 3 | 4 |
| 5\% | 4\% | 3\% | 2\% | 4\% | 2\% | - | 2\% | 2\% | 5\% | 7\% | 5\% | 6\% |
| 55 | 14 | 13 | 11 | 14 | 7 | 5 | 16 | 20 | 8 | 11 | 13 | 12 |
| 24\% | 28\% | 28\% | 28\% | 46\% | 20\% | 38\% | 27\% | 25\% | 36\% | 25\% | 21\% | 22\% |
| 56 | 15 | 11 | 14 | 8 | 10 | 4 | 18 | 17 | 5 | 11 | 13 | 11 |
| 25\% | 31\% | 22\% | 36\% | 25\% | 29\% | $32 \%$ | 30\% | 21\% | 21\% | 25\% | 21\% | 19\% |
| 22 | 3 | 1 | 2 | 1 | 4 | - | 6 | 7 | 4 | 2 | 3 | 9 |
| 10\% | 6\% | 3\% | 4\% | 2\% | 11\% | - | 9\% | 9\% | 17\% | 6\% | 5\% | 16\% |
| 29 | 6 | 8 | 1 | 3 | 3 | 1 | 11 | 15 | 1 | 5 | 11 | 3 |
| 13\% | 13\% | 16\% | 4\% | 8\% | 9\% | 5\% | 19\% | 19\% | 6\% | 12\% | 18\% | 6\% |
| 37 | 7 | 12 | 7 | 4 | 9 | 3 | 6 | 16 | 2 | 9 | 14 | 6 |
| 16\% | 14\% | 26\% | 19\% | 14\% | 26\% | 24\% | 9\% | 20\% | 11\% | 21\% | 23\% | 11\% |
| 20 | 2 | 1 | 3 | - | 1 | - | 3 | 3 | 1 | 2 | 4 | 11 |
| 9\% | 4\% | 2\% | 7\% | - | 2\% | - | 5\% | 4\% | 3\% | 4\% | 6\% | 19\% |
| 65 | 16 | 14 | 12 | 15 | 7 | 5 | 18 | 22 | 9 | 14 | 16 | 16 |
| 28\% | 32\% | 30\% | 30\% | 50\% | 22\% | 38\% | 29\% | 27\% | 41\% | 32\% | 27\% | 28\% |
| 51 | 10 | 9 | 3 | 3 | 7 | 1 | 17 | 22 | 5 | 8 | 14 | 13 |
| 22\% | 19\% | 19\% | 8\% | 11\% | 20\% | 5\% | 28\% | 28\% | 23\% | 18\% | 23\% | 22\% |
| 2.98 | 3.04 | 2.96 | 3.27 | 3.41 | 2.92 | 3.37 | 2.81 | 2.78 | 3.20 | 3.12 | 2.88 | 3.08 |

